Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Meghan Mills

Nurse Practitioner, Gerontology Tupelo, MS Nurse Practitioner

NPI 1881005858 CMS profile 10700161

830 S Gloster St, Tupelo, MS 38801

Open in the dashboard

General payments

$10,309

705 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meghan Mills of Tupelo, MS is reported in the CMS Open Payments database as having received $10,309 across 705 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,256 145
2024 General $1,995 134
2023 General $2,133 147
2022 General $1,978 146
2021 General $1,948 133

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meghan Mills
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Meghan Mills were reported at $2,256. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Meghan Mills Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,948 $133 $44–$396 $132
2022 $1,978 $142 $48–$452 $149
2023 $2,133 $158 $53–$482 $160
2024 $1,995 $171 $55–$533 $164
2025 $2,256 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,389 106 payments
  2. Novo Nordisk Inc $1,010 62 payments
  3. Lilly USA, LLC $1,004 84 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $773 65 payments
  5. AstraZeneca Pharmaceuticals LP $737 38 payments
  6. Amgen Inc. $675 48 payments
  7. Pfizer Inc. $586 49 payments
  8. Novartis Pharmaceuticals Corporation $559 38 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $529 39 payments
  10. Daiichi Sankyo Inc. $444 24 payments
  11. Other $2,603 152 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,143 703 payments
  2. Education $166 2 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $845 58 payments
  2. FARXIGA $608 30 payments
  3. Ozempic $605 36 payments
  4. Kerendia $529 39 payments
  5. RYBELSUS $504 31 payments
  6. QULIPTA $501 37 payments
  7. MOUNJARO $493 33 payments
  8. JARDIANCE Diabetes $469 48 payments
  9. JARDIANCE Diabetes $449 35 payments
  10. INJECTAFER $444 24 payments
  11. Other $7,879 552 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 106 drugs

Part D claims

4,059

Median for Nurse Practitioner: 389

Drug cost

$310,488

Median for Nurse Practitioner: $21,885

Branded share of claims

21.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 75 $77,313
Jardiance Empagliflozin Brand 89 $57,727
Eliquis Apixaban Brand 23 $22,244
Farxiga Dapagliflozin Propanediol Brand 32 $22,024
Gemtesa Vibegron Brand 36 $16,335
Entresto Sacubitril/Valsartan Brand 21 $14,880
Tresiba Flextouch U-200 Insulin Degludec Brand 12 $13,067
Trulicity Dulaglutide Brand 11 $12,017
Synjardy Xr Empagliflozin/Metformin Hcl Brand 18 $9,933
Xarelto Rivaroxaban Brand 12 $7,557

The 10 drugs with the highest cost, of 106 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 114 billing codes

Paid by Medicare

$396,283

Of which drugs: $174,168

Medicare patients

998

Average age 77

Services billed

23,832

598 women, 400 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 38%
Ischemic heart disease 37%
Chronic kidney disease 37%
Depression 35%
Osteoporosis 23%
Atrial fibrillation 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 69 4,380 $89,832
Injection, inclisiran, 1 mg J1306 Office 17 5,680 $54,073
Vaccine for influenza for injection into muscle 90662 Office 127 130 $10,528
Pcv20 vaccine im 90677 Office 25 25 $7,210
Injection, methylprednisolone acetate, 1 mg J1010 Office 49 2,785 $272
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 59 312 $26
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 12 15 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
$170 32 —
INJECTAFER
$141 — —
UBRELVY
$133 — —
REXULTI
$113 — —
Kerendia
$110 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

705 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record